Health
Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial – The Lancet
Dabrafenib plus trametinib combination treatment showed promising activity in patients
with BRAFV600E-mutated biliary tract cancer, with a manageable safety profile. Routine
testing for BRAFV600E mutations should be considered in patients with biliary tract
c…
We use cookies to help provide and enhance our service and tailor content and ads. By continuing you agree to the use of cookies.
Copyright © 2020 Elsevier Inc. except certain content provided by third parties.
Privacy Policy Terms and Conditions…
-
Noosa News22 hours agoMeet Chad Burgess, Pauline Hanson’s One Nation Party
-
Noosa News23 hours agoWestern Queensland graziers begin grim stock count after catastrophic floods
-
General21 hours agoTyler Wright soaks up Bells Beach return as poor conditions at Rip Curl Pro sees men’s opening round called off
-
General21 hours agoTruck driver charged with causing death by dangerous driving after highway crash